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Introduction
Prostate cancer is the most common male solid cancer in 
the world. In developed countries prostaqte-specific anti-
gen (PSA) testing/screening has increased our estimates of 
incidence.1 In the UK, the incidence of localised prostate 
cancer at presentation has increased over the last decade, 
while the rate of metastatic disease at presentation has 
decreased.2 However, the impact that PSA testing and sub-
sequent treatment of localised disease has had on prostate 
cancer-specific mortality (PCSM) is questionable3,4 and 
there is therefore a drive to manage men with less invasive 
therapy or surveillance alone.5 Risk stratification tools 
have repeatedly been shown to outperform clinicians at 
identifying the correct men in whom to pursue these more 
conservative management strategies.6
New classification systems
Caras and Sterbis grouped risk stratification tools into 
those predicting the likelihood of cancer before biopsy, 
those predicting the behaviour of biopsy-confirmed can-
cer after diagnosis but, before treatment or surveillance, 
and nomograms predicting behaviour after treatment.7 
This article will focus on approaches to risk stratification 
of men with biopsy-confirmed prostate cancer, prior to 
treatment.
Currently, men with localised prostate cancer are risk 
stratified according to their PSA at diagnosis, clinical stage 
and Gleason grade at biopsy. In the UK, the National 
Institute for Health and Care Excellence (NICE) has 
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published a scoring system that groups men according to 
the risk of prostate cancer recurrence following treatment. 
In brief, there are three groups: low-risk, for men with a 
PSA less than 10 ng/ml, Gleason score of 6 or less and 
clinical stage T1–T2a; the intermediate-risk group for men 
with a PSA of 10–20 ng/ml, Gleason score of 7, or clinical 
stage T2b; and a high-risk group for men with a PSA 
greater than 20 ng/ml, Gleason score of 8–10 or clinical 
stage T2c or greater. However, these guidelines draw on 
studies that have never been assessed against PCSM. 
Indeed, the PSA cut-off points are replicated from 
D’Amico’s work in 1998, using biochemical recurrence 
(BR) as a surrogate for aggression, which does not always 
predict PCSM.8,9 Another early attempt at allocating risk, 
the Kattan nomograms, predicted the presence of indolent 
cancers based on a study of clinical stage, Gleason grade, 
PSA and cancer volume in biopsy specimens.10 However, 
the majority of patients in this study underwent radical 
prostatectomy and again outcomes were measured against 
BR. Furthermore, clinical staging has not consistently 
been shown to associate with PCSM in the UK. For exam-
ple, although Reese et al. demonstrated that clinical stag-
ing predicted BR after radical prostatectomy in American 
men,11 Selvadurai et al. showed that clinical staging could 
not predict adverse histology on repeat biopsy for UK men 
undergoing active surveillance.12 There have been no UK 
based studies to show that the above criteria can predict 
PCSM. Despite this, with some relatively minor changes, 
the above clinical parameters are incorporated in over 20 
risk stratification tools.13 Many of these tools are validated 
in populations of men outside the UK, who are undergoing 
radical prostatectomy and are measured against surrogate 
markers other than PCSM.
In 2005 Cooperberg et al. described the cancer of the 
prostate risk assessment (CAPRA) score.14 The score indi-
cates risk on a 1–10 scale by using age and PSA at diagno-
sis, the percentage of biopsy cores which contain cancer, 
Gleason score at biopsy and clinical stage to assign points. 
Although the score was initially validated against predict-
ing BR following radical prostatectomy, it has subse-
quently been shown to predict the risk of bone metastases 
and PCSM in over 10,000 American men with localised 
cancer considering all treatment options. Cooperberg et al. 
showed that for each increase in CAPRA score, there was 
a statistically significant increased risk of prostate cancer-
specific morbidity or mortality.14 However, only 6% of 
men undertook active surveillance/watchful waiting in 
their cohort, despite 49% of patients having a CAPRA 
score of 2 or less.
National and international consortia have also acted on 
evidence to suggest that increasing the number of risk cat-
egories can improve pretreatment risk stratification. The 
National Comprehensive Cancer Network (NCCN) has 
recently updated its risk stratification guidelines to incor-
porate the amount of disease present in prostate biopsy 
cores and include a new very low-risk group. The purpose 
of the very low-risk group is to highlight patients who are 
suitable for surveillance strategies rather than aggressive 
treatment. The drive for creation of the new group came 
from studies such as that conducted by Miller et al., show-
ing that approximately 40% of cancers diagnosed in the 
USA were over-treated.15 Furthermore, in 2008 Beasley 
et al. showed that splitting the intermediate group into 
low-intermediate and high-intermediate groups also 
improved pretreatment risk stratification.16 However, these 
conclusions were due to the high-intermediate group hav-
ing reduced BR rates when given adjuvant androgen dep-
rivation therapy while the low-intermediate group received 
no benefit.13,16
NICE, therefore, highlights that clinical risk stratifica-
tion tools may not be representative of outcomes in the 
UK, not least because of the differences between PSA 
screened populations and ours, and differences in the way 
men are treated.17 A recent study from our institution has 
addressed this and tested the NICE risk groups and a new 
model in a large UK population. This study demonstrated 
poor concordance for the NICE groups in predicting 
PCSM but a significantly improved performance by using 
a more refined risk stratification system.18
Imaging
With advances in magnetic intensity and functional mul-
tiparametric imaging (mpMRI), including dynamic con-
trast enhanced sequences, diffusion weighted imaging 
(MR-DWI), magnetic resonance spectroscopy (MRS) 
and dynamic contrast enhanced MRS, the usefulness of 
magnetic resonance imaging (MRI) has increased drasti-
cally. However, variations in protocols and a lack of diag-
nostic criteria have impeded the widespread adoption of 
mpMRI. The recent joint publication of the prostate 
imaging – reporting and data system version 2 by the 
American College of Radiology and European Society of 
Uroradiology will help standardise the acquisition, inter-
pretation, and reporting of prostate mpMRI19 enabling 
MRI to be incorporated in the pretreatment prostate can-
cer pathway to assess the stage and risk of localised pros-
tate cancer.20
Using MRI, Somford et al. were able to predict extra-
prostatic extension at radical prostatectomy in a cohort of 
183 men accurately in 73.8% of cases, with negative pre-
dictive value highest in men in the low-risk group.21 
Subsequently, Marcus et al. described the addition of 
mpMRI to the NCCN risk stratification tool and found that 
MRI correctly upstaged 12/71 men. Interestingly, the 
majority of upstaged patients were previously classified as 
intermediate risk.22
Moreover, the apparent diffusion coefficient (ADC), 
calculated from DW-MRI, has been shown to correlate 
with prostate cancer aggression23–25 and Hambrook et al. 
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demonstrated that MR-DWI was able to identify prostatic 
lesions that were more representative of final pathology 
following prostatectomy when compared to standard 
10-core transrectal ultrasound-guided (TRUS) biopsy.26 
The use of MRI to risk-stratify prostatic lesions non-inva-
sively is exciting; however, at present ADC values were 
not significantly discriminative for tumours in the transi-
tion zone or for low-risk tumours20,23 but further investiga-
tion is warranted.
Biopsy approach
Currently, 10–12-core TRUS biopsy is standard practice in 
the initial biopsy setting, despite having been shown to 
miss around 30–45% of prostate cancers.27–29 Saturation 
(>20 cores) rectal or transperineal biopsies have been 
advocated to improve the accuracy of clinically significant 
prostate cancer diagnosis. However, in a systematic review, 
Eichler et al. demonstrated that the addition of further 
cores (18–24) did not detect significantly more cancers 
and may have a poorer side effect profile,30 and a survey of 
urologists in the UK revealed that saturation biopsy is 
infrequently used in the initial biopsy setting.17 Advances 
in mpMRI have led to an increasing adoption of MRI-
guided biopsies to improve cancer detection and subse-
quent risk stratification. Pinto et al. used fusion MRI-guided 
biopsies to demonstrate an improved efficiency of diagno-
sis (fewer number of cores needed to detect prostate can-
cer), although the authors were unable to demonstrate a 
change in the rate of detection.31 In 2013, Moore et al. con-
ducted a systematic review of MRI-guided biopsies and 
standard TRUS biopsy and similarly revealed no differ-
ence in the detection of clinically significant cancer while 
confirming the ability of MRI-guided biopsies to detect 
cancer with fewer cores.32 These initial results are exciting 
but mixed and require further investigation. In particular, 
studies determining the value of MRI-guided biopsy com-
pared with TRUS biopsy in relation to long-term outcomes 
are needed.
Histological classification
Since 1966, the Gleason grading has summed the two most 
common grade patterns, each scored from 1 to 5 according 
to glandular architecture, to produce a Gleason score. In 
2005 the International Society of Urological Pathology 
(ISUP) updated the Gleason scoring system.33 The 2005 
ISUP changes were broadly aimed at limiting the scope of 
glandular architecture pattern 3 while widening the scope 
of pattern 4.33,34 Therefore cancers that were previously 
graded 3 were subsequently graded as 4. Indeed, Greenburg 
et al. demonstrated that the adoption of 2005 ISUP scoring 
led to an increased incidence of intermediate and high-risk 
prostate cancer while low-risk prostate cancer incidence 
remained stable in the UK. In 2014, the ISUP committee 
updated guidelines to grade prostate cancer, largely to 
overcome the fear that patients had when assigned a cancer 
diagnosis but with a Gleason score of 6.35 The novel grade 
groups assigns a prognostic score of 1–5 according to the 
glandular pattern (see Table 1). The lead author showed 
these groups to be a more accurate predictor of BR in 
American men undergoing radical treatment.36 Most 
recently, we proposed a new risk stratification system 
incorporating PSA at diagnosis, clinical T stage and the 
novel ISUP grouping system, which improved the predic-
tion of PCSM in a new diagnosis cohort of UK men. These 
findings were based on a cohort of 10,139 men with 789 
prostate cancer deaths over a median of 6.9 years.18
Biomarkers
Numerous prognostic immunohistochemical biomarkers 
have been proposed for use at the prostate biopsy stage. 
However, the majority were developed using prostatec-
tomy cohorts (and often prostatectomy specimens), with 
biochemical recurrence as the endpoint.37 Despite this, 
Ki67, a marker of cellular proliferation, has shown prom-
ise.38 Staining for Ki67 has been shown to be predictive of 
PCSM in both surgically39 and radiotherapy40 treated men 
and predictive of the need for intervention in men under-
going active surveillance,41 although the numbers were 
small. Further larger studies are required to validate and 
incorporate immunohistochemical markers into risk strati-
fication of men at diagnosis.
The use of genetic analysis to predict outcomes in pros-
tate cancer is actively being investigated. Again, many 
studies use prostatectomy samples, in which the amount of 
tissue available makes genetic analysis easier, to develop 
assays. Through advances in genetic analysis and poly-
merase chain reaction methods, we now have the capabil-
ity to detect genetic variants from small amounts of 
material found in biopsy specimens, and several diagnostic 
aids are available, for example, Oncotype Dx,42 Prolaris,43 
Dechipher,44 etc. Many of these assays assess the likeli-
hood of aggressive cancer by analysing the expression of 
genes from isolated RNA.
In 2015, Cullen et al. used the Oncotype Dx assay to 
assess the expression of 12 cancer-related genes from 
biopsy extracted RNA in 93% of 431 racially diverse men 
with intermediate (or less) NCCN risk stratification.45 An 
increasing assay score (on a scale from 0 to 100) predicted 
adverse final pathology, BR and metastatic recurrence 
with hazard ratios per 20 score units of 3.3, 2.9 and 3.8. 
However, the number of men who developed metastasis 
was small (n=5).45 Klein et al. utilised the Decipher test 
consisting of a 22-gene panel RNA analysis in 57 men 
who underwent prostatectomy who were followed up for 
8 years.44 The Decipher test reclassified 46% of men from 
their NCCN classification. However, again, the number of 
events was low (8/57) and when Decipher’s results were 
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analysed in isolation, the number of men who developed 
metastasis with Decipher low, medium and high-risk 
scores were one, five and two.44 This raises the important 
question of how best to incorporate novel markers to clin-
ical risk stratification strategies. In 2013, Cooperberg 
et al. demonstrated the importance of combining the 
Prolaris cell-cycle–progression (CCP) score with the 
CAPRA score. In a cohort of 413 American men undergo-
ing prostatectomy, the authors found that the combined 
CCP-CAPRA score had an improved ability to predict 
BR, when compared to the CCP score or the CAPRA 
score alone.46 However, they were not able to assess 
PCSM or clinical metastasis due to the low number of 
events and used the CCP score from only the dominant 
region of the prostate gland.
Clearly more work needs to be done, not least in diver-
sifying the patient populations in which biomarker studies 
have been conducted. An additional major challenge will 
be to take our understanding of the above risk stratification 
criteria, borne out of our experience in treating all-comers 
with prostate cancer, and relate this to our novel under-
standing of prostate cancer as a highly heterogeneous can-
cer, with five47 or indeed seven48 distinct molecular 
subtypes.
Summary
Risk stratification of men at a pretreatment stage is becom-
ing increasingly important and the era of using Gleason 
grading, PSA and clinical staging alone to stratify men into 
one of three risk categories is coming to an end. Novel risk 
stratification tools will aim to classify men into five (or 
more) categories including a very low-risk group, and the 
splitting of the intermediate-risk group into an intermedi-
ate low and intermediate high-risk group.13,18 In the near 
future one can envisage the incorporation of additional 
information, including MP-MRI findings and genomic 
profiling scores to stratification tools, resulting in more 
accurate risk stratification, leading to improved decision 
making at the pretreatment stage.
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